1. A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer
   Peter F. Lebowitz et al, 2004, Clinical Cancer Research CrossRef
2. Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer
   Tamila Kindwall-Keller et al, 2005, Clinical Cancer Research CrossRef
3. The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
   Zilin Zhang et al, 2021, Frontiers in Pharmacology CrossRef
4. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
   Joyce O’Shaughnessy et al, 2002, Journal of Clinical Oncology CrossRef
5. Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
   M. Michael et al, 2005, Journal of Clinical Oncology CrossRef
6. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis
   Louai Alsaloumi et al, 2020, Oncology Research and Treatment CrossRef
7. Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
   Tyvin A. Rich et al, 2004, Journal of Clinical Oncology CrossRef
8. Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure
   Beth Overmoyer, 2003, Journal of Clinical Oncology CrossRef
9. Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies
   Padma Nadella et al, 2002, Journal of Clinical Oncology CrossRef